NALIRIFOX and other nal-IRI based regimen as sequential therapy after FOLFIRINOX in unresectable pancreatic cancer
Background and objective: Chemotherapy with 5-fluoruracil (5-FU)/folinic acid (FA), irinotecan (IRI) and oxaliplatin (OX) (FOLFIRINOX) is a standard first line treatment in advanced pancreatic cancer. Recently, an alternative regimen with nanoliposomal irinotecan (nal-IRI) (NALIRIFOX) has shown [for full text, please go to the a.m. URL]
Authors
- S. Stegmann
- C Bartz
- C. Neumann-Haefelin
- D Waldschmidt
- N. G. Im
- T. Persigehl
- A. Meyer zu Schwabedissen
- J. Hollnberger
Institutions
- Poliklinik für Endokrinologie, Diabetologie und Präventivmedizin (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2026-06-18
- DOI
- https://doi.org/10.3205/26vzmnrw138
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00